Gout Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Gout is the most common form of inflammatory arthritis in adults, affecting approximately 3–4% of the adult population in high-income countries and rising globally in parallel with increases in obesity, hypertension, and chronic kidney disease. It is caused by the deposition of monosodium urate (MSU) crystals in joints, periarticular structures, and soft tissues as a consequence of sustained hyperuricaemia — a serum urate concentration above the physiological saturation threshold of approximately 6.8 mg/dL (404 µmol/L) at body temperature.

MSU crystals in synovial fluid activate the NLRP3 inflammasome, triggering release of interleukin-1 beta (IL-1β), which drives the intense neutrophilic inflammation responsible for the excruciating pain, swelling, erythema, and warmth of an acute gout attack. Left untreated, attacks typically self-resolve within 7–14 days, but recurrence is the rule: without urate-lowering therapy (ULT), the majority of patients experience a second attack within one year.

Treatment of gout has two distinct phases that should not be conflated:

1. Acute attack treatment: Rapid anti-inflammatory therapy to abort the current attack — colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids.
2. Urate-lowering therapy (ULT): Long-term reduction of serum urate to below the saturation threshold (<6 mg/dL; <5 mg/dL for tophaceous gout) to dissolve existing crystals, prevent future attacks, and reverse tophus formation.

The 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout and the 2016/2022 European Alliance of Associations for Rheumatology (EULAR) recommendations provide the strongest current evidence base for gout management. Both guidelines emphasise that gout is a curable disease with appropriate long-term ULT — a key educational message for patients who often discontinue therapy between attacks when they feel well.

Gout progresses through distinct clinical stages, each with specific treatment implications:

Asymptomatic Hyperuricaemia

Elevated serum urate without symptoms. Most guidelines do not recommend ULT at this stage unless serum urate is very high (>10–11 mg/dL) or associated with urolithiasis. Recent evidence suggests subclinical MSU crystal deposition may occur before the first clinical attack, challenging the traditional definition of asymptomatic hyperuricaemia.

Acute Gout Flare (Podagra and Beyond)

The classic acute attack begins abruptly, often at night, reaching peak intensity within 12–24 hours. The first metatarsophalangeal (MTP) joint of the great toe (podagra) is affected in approximately 70% of first attacks. Other common sites include the ankle, midfoot, knee, wrist, and finger joints. Overlying skin may desquamate after the attack resolves. Triggers include alcohol (particularly beer and spirits), high-purine meals, dehydration, intercurrent illness, surgical stress, and paradoxically — initiation of ULT (due to crystal mobilisation).

Intercritical Gout

The asymptomatic period between attacks. MSU crystals remain present in joints and continue to deposit; attacks recur with increasing frequency and severity as the crystal burden grows. This is the most important period to initiate and maintain ULT.

Chronic Tophaceous Gout

After years of untreated hyperuricaemia, MSU crystals aggregate into macroscopic deposits called tophi — visible as firm, chalky subcutaneous nodules around joints (typically elbows, Achilles tendon, pinna, and fingers). Tophi cause joint destruction, deformity, skin ulceration, and secondary infection. Chronically elevated urate also causes urate nephropathy and increases cardiovascular and renal risk. Tophi dissolve slowly with sustained ULT below target; surgical debridement is occasionally required.

Gout Nephropathy and Urolithiasis

Uric acid is excreted by the kidneys; chronic hyperuricaemia and hyperuricosuria can cause tubular urate deposits (urate nephropathy) and uric acid kidney stones (15–25% of gout patients). Adequate hydration and urinary alkalinisation reduce stone risk; allopurinol reduces urinary uric acid excretion.

The decision to initiate long-term ULT should be based on attack frequency, presence of tophi, comorbidities, and shared decision-making:

Strong Indications for ULT (ACR/EULAR Consensus)

• Two or more gout flares per year.
• Any tophus detected clinically or on imaging (dual-energy CT, musculoskeletal ultrasound).
• Chronic kidney disease (CKD) stage 3 or worse — hyperuricaemia accelerates CKD progression and the renal threshold for urate excretion is reduced, raising crystal burden.
• Urolithiasis associated with uric acid stones.
• Serum urate persistently >9 mg/dL even with infrequent flares.
• Destructive tophaceous joint disease on imaging (erosions, joint damage).

Conditional Indications

• First or second flare in a patient with serum urate >8 mg/dL and presence of comorbidities (hypertension, diabetes, coronary artery disease).
• Young patients (<40 years) — they have decades of cumulative crystal deposition ahead and should be offered ULT after the first or second attack.

When ULT May Be Deferred

• First uncomplicated gout flare with serum urate <8 mg/dL and no comorbidities, provided the patient is committed to dietary and lifestyle modification and understands the need for reassessment.

Timing of ULT Initiation

Historically, ULT was deferred until flare resolution to avoid precipitation of further attacks during crystal mobilisation. The 2020 ACR guideline now conditionally recommends initiating ULT during an acute flare (alongside anti-inflammatory therapy) — this approach has been supported by clinical trial data showing no significant difference in flare duration or intensity with in-flare ULT initiation compared with deferred initiation, and it capitalises on the opportunity for patient education during a symptomatic episode.

Acute Gout Flare Management

Colchicine (first-line)

The AGREE Trial established the low-dose colchicine regimen as standard: 1.2 mg at first sign of attack followed by 0.6 mg one hour later, then 0.5–0.6 mg twice daily until attack resolves. Low-dose colchicine is as effective as high-dose (formerly used) with substantially fewer gastrointestinal side effects (diarrhoea, nausea). Colchicine must be used within 24–36 hours of attack onset to be maximally effective. It is contraindicated with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) and P-glycoprotein inhibitors due to risk of fatal colchicine toxicity; dose adjustment is required in renal impairment.

NSAIDs (first-line alternative)

Indomethacin 50 mg three times daily for 5–7 days has historically been the standard NSAID. Other NSAIDs (naproxen 500 mg BD, diclofenac 50 mg TDS) are equally effective. All NSAIDs must be used with gastroprotection (proton pump inhibitor). Avoid in CKD, peptic ulcer disease, heart failure, and concurrent anticoagulation. The relative contraindication of NSAIDs in many gout patients (who have high rates of cardiovascular and renal comorbidity) limits their utility.

Corticosteroids

Oral prednisolone 30–35 mg/day for 5–7 days, or intramuscular methylprednisolone 80–120 mg, is appropriate when colchicine and NSAIDs are contraindicated or ineffective. Intra-articular triamcinolone (20–80 mg depending on joint size) is highly effective for monoarticular attacks accessible to injection. Oral corticosteroids should not exceed 2 weeks to avoid hypothalamic-pituitary-adrenal suppression. Systemic steroids are avoided in patients with poorly controlled diabetes.

IL-1 antagonists (refractory or contraindicated cases)

Anakinra (subcutaneous, off-label), canakinumab (subcutaneous, licensed in Europe for gout flares), and rilonacept are IL-1β blockers effective for patients in whom colchicine, NSAIDs, and steroids are all contraindicated. Cost limits their widespread use; they are recommended only for refractory or contraindicated cases in most guidelines.

Urate-Lowering Therapy (ULT)

Allopurinol — first-line ULT

A xanthine oxidase inhibitor (XOI) that reduces uric acid synthesis. Starting dose 50–100 mg/day, titrated upward every 2–4 weeks to reach the serum urate target (<6 mg/dL). The maximum licensed dose is 900 mg/day in the UK/Europe; many patients need 300–600 mg. Dose must be adjusted for CKD (risk of allopurinol hypersensitivity syndrome — AHS — increases at higher doses in renal impairment). HLA-B*5801 genotyping before starting allopurinol is recommended in Han Chinese, Thai, and Korean patients (high carrier frequency, associated with severe cutaneous AHS — DRESS syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis).

Febuxostat — second-line XOI

A non-purine XOI licensed for patients who cannot tolerate allopurinol. Starting dose 40 mg, increased to 80 mg/day. More potent than standard allopurinol doses at achieving serum urate target. The CARES trial raised a safety signal for increased cardiovascular mortality in patients with established CVD compared with allopurinol; the FAST trial (2020) in the UK showed no significant difference in major adverse cardiovascular events between febuxostat and allopurinol in an older population. Current guidelines recommend caution in patients with established ischaemic heart disease or heart failure, with allopurinol preferred in this group.

Uricosurics — probenecid, lesinurad

Probenecid increases renal uric acid excretion; effective only if renal function is preserved (eGFR >50 mL/min) and urinary uric acid excretion is not already high. Lesinurad (now withdrawn in most markets) was a selective uric acid reabsorption inhibitor (URAT1 inhibitor) used in combination with allopurinol.

Pegloticase — for refractory tophaceous gout

Pegloticase (Krystexxa) is a pegylated recombinant uricase that metabolises uric acid to allantoin (water-soluble, easily excreted). IOP reduction is dramatic — serum urate drops to near-zero within hours of infusion. Given intravenously every 2 weeks. Indicated for severe, chronic tophaceous gout failing conventional ULT. Major limitation: anti-drug antibodies develop in up to 40% of patients, causing loss of response and severe infusion reactions. Combination with immunosuppression (methotrexate, azathioprine) — the MIRROR open-label trial protocol — can extend durable response rates to >70%. Cost is prohibitive (USD 5,000–7,000 per infusion in the USA).

Prophylaxis Against Flares During ULT Initiation

Starting or uptitrating ULT mobilises crystal deposits and paradoxically triggers flares. Anti-inflammatory prophylaxis — low-dose colchicine 0.5 mg once or twice daily — should be continued for at least 6 months after reaching the serum urate target (or until tophi have resolved, if present). If colchicine is contraindicated, low-dose NSAIDs or low-dose prednisolone are acceptable alternatives.

Effective gout management offers profound short-term and long-term benefits:

• Rapid acute attack resolution: Colchicine, NSAIDs, or steroids resolve the acute attack within 3–7 days, ending the disabling pain that severely limits function and quality of life during flares.
• Attack prevention: Sustained serum urate below target (<6 mg/dL) reduces attack frequency dramatically. In clinical trials of ULT, patients achieving the serum urate target had an 80–90% reduction in annual flare rate after the first year of treatment.
• Tophus resolution: Tophi dissolve when serum urate is maintained below saturation. Radiographic studies show progressive tophus reduction over 12–36 months of effective ULT. Complete tophus resolution is achievable in most patients within 2–5 years of sustained ULT at target, reducing joint damage, pain, and disability.
• Prevention of joint destruction: Chronic tophaceous gout causes cartilage loss, bone erosions, and permanent joint deformity. Early initiation and maintenance of ULT prevents these irreversible changes and preserves joint function.
• Renal protection: Hyperuricaemia is independently associated with CKD progression. ULT with allopurinol or febuxostat has been shown in observational studies and some randomised trials to slow eGFR decline, though this endpoint remains an area of active investigation.
• Cardiovascular risk reduction: Gout is associated with a 60–80% increased risk of myocardial infarction and 40% increased risk of stroke. Whether ULT directly reduces cardiovascular events (beyond IOP reduction and anti-inflammatory effects) remains debated, but optimal gout management is an integral component of cardiovascular risk factor control in these high-risk patients.

Colchicine Risks

Gastrointestinal toxicity (diarrhoea, nausea, vomiting, abdominal cramps) is the most common adverse effect; the low-dose regimen reduces but does not eliminate this. Colchicine neuromyopathy (proximal muscle weakness and neuropathy) occurs with prolonged use, particularly in renal impairment. Potentially fatal drug interactions: co-prescription with clarithromycin, cyclosporin, or statins in the context of renal impairment can cause life-threatening colchicine accumulation. Bone marrow suppression with agranulocytosis can occur at toxic doses.

NSAID Risks

Gastrointestinal bleeding and peptic ulceration (risk reduced with concomitant PPI), acute kidney injury (particularly in patients with pre-existing CKD, diabetes, or heart failure), and cardiovascular events (sodium retention, hypertension, platelet inhibition) are the primary concerns. Indomethacin in particular has a higher risk of CNS side effects (headache, confusion) in elderly patients.

Corticosteroid Risks

Short-term steroids (5–7 days) carry low risk. Prolonged courses cause hyperglycaemia (particularly in diabetic patients — steroid-induced hyperglycaemia is predictable and requires monitoring and dose adjustment of diabetes medications), insomnia, mood disturbance, hypertension, and immune suppression.

Allopurinol Risks

Allopurinol hypersensitivity syndrome (AHS): a spectrum from mild rash to life-threatening DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), Stevens-Johnson syndrome, or toxic epidermal necrolysis. AHS incidence is 0.1–0.4%; mortality of severe AHS is 20–25%. Risk factors: renal impairment, starting doses >100 mg/day, HLA-B*5801 genotype (common in Southeast Asian populations). Mitigation: start low (50–100 mg/day), titrate slowly, screen high-risk populations. Drug interactions: azathioprine and 6-mercaptopurine levels rise dangerously when co-prescribed with allopurinol (both metabolised by xanthine oxidase) — dose of immunosuppressant must be reduced by 75%.

Febuxostat Risks

Caution in cardiovascular disease (CARES trial signal). Liver function test elevation; elevated creatinine (monitor renal function). Avoid with azathioprine/6-MP (same interaction as allopurinol).

Pegloticase Risks

Infusion reactions (anaphylaxis, rigors, urticaria) occur in 25–40% of patients who develop anti-drug antibodies. Pre-medication with antihistamines, paracetamol, and IV corticosteroids is mandatory. Infusions must be administered in facilities capable of managing anaphylaxis.

Serum Urate Targets

The cornerstone of ULT monitoring is serial serum urate measurement to confirm that target has been reached and sustained:

• General target: Serum urate <6 mg/dL (360 µmol/L) — below the saturation threshold, ensuring no new crystal deposition and dissolution of existing crystals.
• Tophaceous gout target: Serum urate <5 mg/dL (300 µmol/L) — more aggressive target accelerates tophus dissolution and is recommended by the 2022 EULAR guidelines in the presence of tophi or severe disease.
• Avoid over-reduction: Very low serum urate (<3 mg/dL) is not recommended as a therapeutic goal — uric acid has antioxidant properties in human physiology and very low levels may carry neurological risks (though this remains controversial and under investigation).

Monitoring Schedule

Serum urate should be measured every 4–6 weeks during ULT titration until target is achieved, then every 6 months once stable. Renal function (creatinine, eGFR), complete blood count, and liver function tests should be checked at baseline and periodically during ULT. In patients on allopurinol with CKD, more frequent renal monitoring is essential.

Flare Frequency During Titration

Patients should be warned explicitly that gout flares are common in the first 3–12 months of ULT as crystal stores are mobilised — this is not a sign that ULT is not working or should be stopped. Many patients discontinue ULT at this stage, leading to long-term treatment failure. Anti-inflammatory prophylaxis (colchicine 0.5 mg BD) should be maintained throughout the first 6 months of ULT, or until tophi have resolved if present.

Imaging Follow-up

Musculoskeletal ultrasound (US) can detect the characteristic double-contour sign of MSU crystal deposition on cartilage, and tophi not visible clinically. Dual-energy CT (DECT) accurately quantifies tophus volume and crystal burden; serial DECT can objectively document tophus resolution with ULT. These imaging tools are most useful in diagnosing uncertain cases or quantifying disease burden rather than routine monitoring.

Long-term Considerations

Gout is effectively a permanent indication for ULT in patients with recurrent attacks, tophi, or comorbid CKD or urolithiasis. Stopping ULT is associated with recurrence of hyperuricaemia and return of crystal deposition within months. Patients should be counselled that ULT is a lifetime medication, not a short-term course.

Gout treatment costs span a wide range from the highly affordable to the prohibitively expensive, depending on the agent and healthcare system:

• Generic colchicine: Widely available as a generic; typically USD 0.10–0.50 per tablet in most markets. A short course for acute attack costs USD 2–10. Long-term prophylaxis at 0.5 mg/day costs USD 15–50 per month depending on market.
• Generic NSAIDs: Naproxen and ibuprofen are among the least expensive medications available globally — a 5-day course for acute gout costs USD 1–5 at generic prices.
• Generic allopurinol: Extremely inexpensive — one of the most cost-effective long-term therapies in medicine. A month's supply of allopurinol 300 mg costs USD 3–10 as a generic; it is included on the WHO Essential Medicines List. Total annual cost of allopurinol therapy is typically USD 50–150, making it highly accessible.
• Febuxostat: Branded (Adenuric, Uloric) costs USD 150–400 per month. Generic febuxostat is now available in many markets (patents expired in most countries by 2019–2021) at USD 20–80 per month.
• Pegloticase (Krystexxa): A 2-week infusion cycle costs approximately USD 5,000–7,000 in the USA; a full 6-month treatment course can cost USD 65,000–90,000. Prior authorisation from insurance is required; this limits use to truly refractory severe tophaceous gout. Outside the USA, access is limited by cost and approval status.
• Canakinumab (Novartis): A single dose for acute gout flare costs USD 10,000–15,000 in the USA; reserved for patients with no other options.
• Disease burden costs of untreated gout: Work absence, reduced productivity, A&E attendances, and long-term joint damage surgery represent indirect and direct costs of poorly managed gout. Economic analyses consistently show that effective ULT with allopurinol is highly cost-effective, reducing hospitalisation and gout-related healthcare utilisation.

Diet and lifestyle modifications can reduce serum urate levels and attack frequency, but they are insufficient as the sole treatment for most gout patients — they should complement, not replace, ULT:

Dietary Purines

Purines are metabolised to uric acid. High-purine foods that should be avoided or strictly limited include organ meats (liver, kidneys, sweetbreads, brain), game meats (venison, grouse), red meat in excess, shellfish (particularly mussels, scallops, anchovies, sardines), yeast extracts (Marmite, Vegemite). Moderate-purine foods (poultry, other seafood, legumes) need not be eliminated but should be consumed in moderation. Diet modification alone typically reduces serum urate by approximately 1–2 mg/dL — rarely sufficient to reach target without ULT.

Alcohol

Alcohol — particularly beer (containing guanosine, a potent purine precursor) and spirits — markedly raises serum urate by increasing purine production and reducing renal excretion. Beer raises serum urate substantially more than wine per gram of alcohol. Wine in moderation (1–2 units/day) has minimal effect on urate. Alcohol abstinence or strict limitation is a core lifestyle recommendation for all gout patients.

Fructose and Sugar-sweetened Beverages

Fructose — abundant in soft drinks, fruit juices, and high-fructose corn syrup — is the only carbohydrate that raises serum urate, through activation of the xanthine oxidase pathway during hepatic fructose metabolism. The marked rise in gout prevalence since the 1980s correlates strongly with increased consumption of sugar-sweetened beverages. These should be eliminated.

Dairy Products

Low-fat dairy (skimmed milk, low-fat yoghurt) is uricosuric and protective — it reduces serum urate and gout risk. Regular dairy consumption is actively recommended. Full-fat dairy has no uricosuric benefit.

Hydration

Adequate fluid intake (2–3 litres/day) promotes renal uric acid excretion and reduces uric acid kidney stone risk. Urinary alkalinisation with potassium citrate (sodium bicarbonate or citrate supplements) raises urinary pH above 6.0, greatly increasing urate solubility and excretion — particularly useful in patients with uric acid urolithiasis.

Weight Management

Obesity is a major driver of hyperuricaemia — adipose tissue increases purine turnover and insulin resistance reduces renal urate excretion. Weight loss (through diet and exercise) reduces serum urate by 0.5–1.5 mg/dL and attack frequency. Bariatric surgery reduces serum urate substantially (through caloric restriction and insulin sensitisation) and long-term reduces gout prevalence in morbidly obese patients.

Surgical Management of Tophaceous Gout

When tophi cause mechanical complications (joint limitation, nerve compression — e.g., carpal tunnel syndrome from wrist tophi, skin ulceration, secondary infection) and cannot be resolved with ULT in a reasonable timeframe, surgical debridement or excision may be required. Surgery in the context of active gout is associated with high wound complication rates; ideally tophi are reduced with ULT first. Joint replacement (arthroplasty) may be required for destroyed joints with intractable pain.